瑞德西韦

瑞德西韦（CAS 1809249-37-3）的独立参考数据，整理自公开化学数据库。

各数据库的登记标识

计算分子描述符

在册的记载用途

Remdesivir is indicated for the treatment of adult and pediatric patients 28 days of age and older and weighing at least 3 kg for coronavirus disease 2019 (COVID-19) infection requiring hospitalization. It is also indicated for the treatment of non-hospitalized patients with mild-to-moderate COVID-19, who are at high risk for progression to severe COVID-19, including hospitalization or death. Remdesivir was originally granted FDA Emergency Use Authorization (EUA) on May 1, 2020, for use in adults and children withRemdesivir is an antiviral nucleotide analogue used for therapy of severe novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome (SARS) coronavirus 2 (CoV-2) infection. Remdesivir therapy is given intravenously for 3 to 10 days and is frequently accompanied by transient, reversible mild-to-moderate elevations in serum aminotransferase levels but has been only rarely linked to instances of clinically apparent liver injury, its hepatic effects being overshadowed by the systemic effects

同义词与商品名

Remdesivir; 1809249-37-3; Veklury; GS-5734; 3QKI37EEHE; remdesivirum; GS 5734; GS5734; Remdesivir [USAN]; CHEBI:145994; DTXSID701022537; RefChem:6679; 13C3 GS-5734; 13C3-GS-5734; GS-465124; GS-829143

GHS 危害分类

Reported hazard statements	H302 (33.3%), H315 (33.3%), H319 (33.3%), H335 (33.3%), H372 (33.3%), H373 (66.7%)

H302 (33.3%): Harmful if swallowed [Warning Acute toxicity, oral]

H315 (33.3%): Causes skin irritation [Warning Skin corrosion/irritation]

公开数据库对它的描述

Remdesivir · CAS 1809249-37-3 · C27H35N6O8P. UNII 3QKI37EEHE.

数据来源：PubChem / Wikidata；与随货 COA 不一致时以 COA 为准。